多西他赛联合卡铂治疗晚期非小细胞肺癌的疗效

Efficacy of docetaxel plus carboplatin combination chemotherapy for advanced non-small cell lung cancer

背景与目的化疗是治疗晚期非小细胞肺癌的主要方法。本研究旨在分析多西他赛加卡铂治疗晚期非小细胞肺癌的疗效。方法本组共治疗64例ⅢB、Ⅳ期非小细胞肺癌,采用多西他赛75mg/m2静脉注射,第1天,卡铂AUC=5静脉注射,第2天。结果全组总有效率CR+PR为42.6%,临床获益率CR+PR+SD为68.9%,中位生存期14个月,1年生存率45.23%。初治病例1年生存率48.84%,中位生存期14个月;复治病例1年生存率37.89%,中位生存期12个月,两组之间差异有统计学意义(P=0.0233)。ⅢB期病例1年生存率44.86%,中位生存期15个月;Ⅳ期病例1年生存率39.75%,中位生存期12个月,两组之间差异有统计学意义(P=0.0354)。腺癌、鳞癌患者的疗效差异无统计学意义。主要毒副反应为粒细胞下降、乏力、恶心呕吐及脱发等。结论多西他赛联合卡铂方案治疗晚期非小细胞肺癌疗效可靠,副反应轻微,可作为晚期非小细胞肺癌的一线和二线治疗方案。

Background and objective Chemotherapy is one of the important treatment methods for advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy of docetaxel combined with carboplatin in treatment of advanced NSCLC. Methods Sixty-four stage ⅢB/Ⅳ NSCLC patients were treated with docetaxel (75 mg/m2 intravenously, on day 1) and carboplatin (AUC=5 intravenously, on day 2). Results The overall response rate (RR) was 42.6%, median survival time (MST) was 14 months, and 1-year survival rate was 45.23%. In initial treatment group, 1-year survial rate was 48.84% and MST was 14 months, and 37.89% and 12 months respectively in retreatment group (P=0.0233). The 1-year survial rate and MST of stage ⅢB patients were 44.86% and 15 months, and 39.75% and 12 months respectively in stage Ⅳ patients (P=0.0354). There was no significant difference in efficacy between squamous cell carcinoma and adenocarcinoma patients. The major adverse effects were granulopenia, fatigue, nausea, vomiting and alopecia. Conclusion The combination of docetaxel and carboplatin has a high response rate and tolerable side effects in treatment of advanced NSCLC, which can be adopted as both the first-line and second-line treatment.